Influence and curative effect observation of two drugs on colonic transit function of patients with chronic functional constipation(CFC)
- VernacularTitle:两种药物联合对慢性功能性便秘患者结肠传输功能的影响及疗效观察
- Author:
Yonghai LU
1
;
Jianfeng CHEN
Author Information
1. 浙江省青田县中医医院普外科
- Keywords:
Chronic functional constipation(CFC);
Bifid triple viable capsules;
Lactulose;
Reoccurrence
- From:
China Modern Doctor
2015;(13):59-61,64
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss influence and curative effect of bifid triple viable capsules combined with lactulose on colonic transit function of patients with chronic functional constipation(CFC). Methods A total of 78 cases with CFC were divided into research group and control group randomly. The patients in two groups were given basic medical treatment, such as diet structure adjustment, plenty of water, defecation training and etc. The patients in research group were additionally bifid triple viable capsules combined with lactulose oral fluid, with 420 mg bifid triple viable cap-sules, three times a day with warm boiled water, and 10 mL lactulose oral fluid, three times a day, 30 minutes before dinner for 6 weeks. The patients in control group were only given lactulose oral fluid with the same method, dose and course of treatment were same as in research group. The changes of total colonic transit time (TCTT) in two groups before and after medical treatment were observed, and the clinical curative effect, adverse drug reactions(ADR) and re-occurrence rate of one-year following-up were compared as well. Results After 6 weeks'treatment, TCTT in two groups were obviously declined than before (P<0.05 or P<0.01), and the declining rate in research group was much higher than that in control group (P<0.05). The total clinical efficiency of patients in research group was much higher than that in control group (χ2=5.19, P<0.05). 6 cases of ADR were appeared in two groups during the medical treatment, with 4 and 2 cases in control group and research group respectively with light symptom, and after comparing the occurrence rates in two groups, no statistical differences were appeared (χ2=0.18, P>0.05). According to one-year following-up, the reoccurrence in research group was much lower than that in control group (χ2=5.19, P<0.05). Conclusion Compare with pure lactulose oral fluid, bifid triple viable capsules combined with lactulose oral fluid have better curative effect and with favorable security on CFC, which can obviously improve the colonic transit function, shorten TCTT, improve constipation symptom and reduce the reoccurrence rate.
